Drug Profile
Research programme: neuropsychotherapeutics - Afraxis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Afraxis
- Class
- Mechanism of Action P21 activated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; CNS disorders; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in USA
- 16 Jul 2016 No recent reports of development identified for research development in Schizophrenia in USA